Mechanisms Mediating the Effects of γ-Tocotrienol When Used in Combination with PPARγ Agonists or Antagonists on MCF-7 and MDA-MB-231 Breast Cancer Cells
γ-Tocotrienol is a natural vitamin E that displays potent anticancer activity, and previous studies suggest that these effects involve alterations in PPARγ activity. Treatment with 0.5–6 μM γ-tocotrienol, 0.4–50 μM PPARγ agonists (rosiglitazone or troglitazone), or 0.4–25 μM PPARγ antagonists (GW96...
Saved in:
Main Authors: | Abhita Malaviya, Paul W. Sylvester |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2013-01-01
|
Series: | International Journal of Breast Cancer |
Online Access: | http://dx.doi.org/10.1155/2013/101705 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The Role of PPARγ in the Transcriptional Control by Agonists and Antagonists
by: Tamotsu Tsukahara
Published: (2012-01-01) -
MicroRNA-1 Inhibits the Growth of Breast Cancer Cells MDA-MB-231 and MCF-7 Treated with Hydatid Cyst Fluid
by: Hadis Jafari, et al.
Published: (2024-01-01) -
Synthesis and Experimental Validation of New Designed Heterocyclic Compounds with Antiproliferative Activity versus Breast Cancer Cell Lines MCF-7 and MDA-MB-231
by: Vincenza Barresi, et al.
Published: (2017-01-01) -
Identification of Bexarotene as a PPARγ Antagonist with HDX
by: David P. Marciano, et al.
Published: (2015-01-01) -
PPARγ and Its Agonists in Chronic Kidney Disease
by: Yuhua Ma, et al.
Published: (2020-01-01)